Skip to content

The Study of intracavitary autologous blood platelet-rich plasma injection to the prognosis of patients with intracerebral hemorrhage

The Study of intracavitary autologous blood platelet-rich plasma injection to the prognosis of patients with intracerebral hemorrhage

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300079075
Enrollment
Unknown
Registered
2023-12-25
Start date
2022-08-01
Completion date
Unknown
Last updated
2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertensive intracerebral hemorrhage

Interventions

Treat group:PRP3ml was slowly injected into the hematoma
Control group:5ml of sterile normal saline was slowly injected into the hematoma

Sponsors

Department of Neurosurgery ,General Hospital of Southern Theater Command, PLA
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Age =18 years old, =70 years old; 2. No aspirin, hydroclopidogrel, indobuprofen and other antiplatelet drugs were taken within 1 week before the onset of ICH; No history of using rivaroxaban, dabigatran, heparin and other anticoagulant drugs; 3. No history of infection; 4. Routine blood test showed no abnormality in platelet and hemoglobin; 5. The patient was diagnosed with hypertensive cerebral hemorrhage, and the volume of intracranial hematoma shown by CT was less than 60ml, and there was no clinical tendency of cerebral hernia.

Exclusion criteria

Exclusion criteria: 1. Age 70 years old; 2. Antiplatelet drugs such as aspirin, hydroclopidogrel and indolbuprofen, or anticoagulant drugs such as rivaroxaban, dabigatron and heparin were taken within 1 week before the onset of ICH; 3. suffer from infectious diseases; 4. Patients with non-hypertensive cerebral hemorrhage; 5.CT confirmed that the intracranial hematoma was larger than 60ml or clinically indicated that the patient had a tendency of cerebral hernia; 6. Patients with malignant tumor, intracranial infection, severe cardiovascular disease, moderate to severe hepatorenal insufficiency or the surgeon thought it was not suitable for inclusion.

Design outcomes

Primary

MeasureTime frame
Modified Rankin Scale;

Secondary

MeasureTime frame
Glasgow Outcome Scale ;muscle strength;Montreal Cognitive Assessment;Mini-Mental State Examination;HamiltonDepressionScale;White matter bundle density;

Countries

China

Contacts

Public ContactHongmin Bai

Department of Neurosurgery ,General Hospital of Southern Theater Command, PLA

baihmfmmu@163.com+86 186 6461 4266

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026